lactam antibiotics in clinical use and can be regarded as a possible alternative to gentamicin.
Ceftazidime (CAZ) is a new cephalosporin which seems to combine very high intrinsic activity against a wide range of pathogenic bacteria, including Pseudomonas aeruginosa, with a metabolic stability (4, 6, 7) . We assume that the greatest use of compounds like CAZ and cefotaxime will be in hospitals where specialized units for the treatment of substantial numbers of compromised patients are located. In this type of unit, whatever precautions are taken, highly resistant or unusual strains of bacteria or both emerge, and outbreaks of infection occur (see recent communication by Gardner et al. [2] ). Thus, we though it worthwhile to study the activity of CAZ against a selection of organisms likely to cause problems in therapy isolated at the Royal Free Hospital, where there are large numbers of patients with liver disease, renal transplants, or leukemia. We have compared CAZ with cefuroxime (CXM), which is currently the only injectable cephalosporin freely available at the above hospital.
A total of 201 strains were tested. These comprised: 21 Results for the 201 strains tested are shown in Table 1 . It is clear that CAZ is considerably more active against almost all species than is CXM. This difference is most marked against the three species of Pseudomonas, S. marcescens, P. vulgaris, and P. morganii. CAZ appears to be slightly more active against the P. fluorescens and P. pickettii strains than against P. aeruginosa. CAZ is less active against S. epidermidis than is CXM, a finding already reported for S. aureus by Wise et al. (7) .
CAZ thus closely resembles cefotaxime (3), except that the former is about four times more active in vitro against P. aeruginosa. As indi-ANTIMICROB. AGENTS CHEMOTHER. epidermidis, a species which in our experience is often methicillin resistant and can cause considerable therapeutic problems (1). Table 2 shows how the MIC of CAZ changed with inoculum size for 197 strains. The only species which showed a great decrease in susceptibility with the larger inoculum was P. vulgaris: growth of this species was very markedly reduced by CAZ, but a small amount of growth did occur even at higher concentrations. Thus, two endpoints were discernible with large inocula of this species: that at which luxuriant growth stopped (which was very similar to the MIC obtained with a small inoculum), and that at which any visible growth was prevented (which was often in excess of 64 ,tg/ml).
CAZ appeared to have similar activities against 41 strains under anaerobic, aerobic, and hypercapnic conditions (Table 3 ). This property is favorable, in contrast to our results with gentamicin (5). The latter antibiotic was severalfold less active under hypercapnic or anaerobic conditions, such as may occur in abscesses or in pneumonia.
We are very encouraged by the activity of CAZ against problem bacterial strains. CAZ had an activity similar to that of cefotaxime, but by contrast it has the advantage of being metabolically stable (4) . This means that antibacterial activity in the body will be easier to predict and Figure 2 is incorrect and should be replaced by the following. The original legend is correct. 
